Zoetis Inc. $ZTS Stock: International Assets Investment Management LLC Raises Position

Key Points

• Institutional buying increased: International Assets Investment Management raised its Zoetis stake by 204.8% in the third quarter to 20,000 shares, worth about $1.4 million. Institutional investors collectively own 92.8% of the company.
• Analyst sentiment is mostly neutral: Six analysts rate ZTS Buy, 12 Hold and one Sell; the consensus rating is Hold with a $93.79 price target. Several firms recently cut their targets.
• Zoetis reported quarterly EPS of $1.87, slightly above estimates, while revenue of $2.47 billion fell short of forecasts and declined 0.2% year over year. The company declared a $0.53 quarterly dividend, equal to a 2.5% yield.

International Assets Investment Management LLC boosted its position in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 204.8% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 20,000 shares of the company's stock after buying an additional 13,439 shares during the quarter. International Assets Investment Management LLC's holdings in Zoetis were worth $1,397,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ZTS. Flossbach Von Storch SE acquired a new position in shares of Zoetis during the 2nd quarter worth approximately $302,601,000. BlackRock Inc. lifted its position in shares of Zoetis by 10.8% during the 2nd quarter. BlackRock Inc. now owns 39,430,181 shares of the company's stock valued at $2,833,453,000 after buying an additional 3,845,869 shares in the last quarter. Ruane Cunniff & Goldfarb L.P. acquired a new stake in Zoetis in the 1st quarter valued at $286,660,000. Southpoint Capital Advisors LP grew its stake in Zoetis by 340.0% in the 1st quarter. Southpoint Capital Advisors LP now owns 2,200,000 shares of the company's stock valued at $260,062,000 after acquiring an additional 1,700,000 shares during the period. Finally, Carmignac Gestion acquired a new stake in Zoetis in the 2nd quarter valued at $113,230,000. Hedge funds and other institutional investors own 92.80% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on ZTS. Stifel Nicolaus lowered their price objective on Zoetis from $85.00 to $80.00 and set a "hold" rating on the stock in a report on Thursday, August 20th. Cantor Fitzgerald set a $94.00 target price on Zoetis in a report on Tuesday, August 25th. JPMorgan Chase & Co. decreased their target price on Zoetis from $130.00 to $115.00 and set an "overweight" rating on the stock in a research report on Friday, August 7th. The Goldman Sachs Group initiated coverage on Zoetis in a research note on Friday, October 16th. They issued a "neutral" rating and a $74.00 price target on the stock. Finally, Citigroup dropped their price target on Zoetis from $112.00 to $96.00 and set a "buy" rating for the company in a research report on Tuesday, August 11th. Six research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $93.79.

Zoetis Trading Up 0.0%

Shares of Zoetis stock opened at $83.19 on Wednesday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The stock's 50 day simple moving average is $75.27 and its 200-day simple moving average is $93.22. The stock has a market cap of $34.38 billion, a P/E ratio of 12.64, a P/E/G ratio of 1.23 and a beta of 0.67. Zoetis Inc. has a 1-year low of $68.77 and a 1-year high of $132.49.

Zoetis (NYSE:ZTS - Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping analysts' consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%. The firm had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same quarter last year, the business posted $1.76 earnings per share. The firm's revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Analysts predict that Zoetis Inc. will post 6.15 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Stockholders of record on Friday, October 30th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Friday, October 30th. Zoetis's payout ratio is currently 34.93%.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and markets medicines, vaccines, diagnostics, genetic products and related services for animals. Its offerings support the prevention, diagnosis and treatment of disease in both companion animals, including dogs, cats and horses, and livestock such as cattle, swine, poultry and fish.

The company's product portfolio includes prescription medicines, parasiticides, vaccines, veterinary diagnostics and animal genetics.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.